MedDataX Logo

Utility of Point Shear-wave Elastography to Assess for Hepatic & Pancreatic Fibrosis in Pediatric CF Patients

NCT ID: NCT03264950

Last Updated: 2017-08-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-01

Study Completion Date

2018-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Diagnosis of hepatic fibrosis is challenging as specific tests for detection of fibrosis in pediatric Cystic Fibrosis associated liver disease (CFALD) have not been developed and existing investigations do not correlate well with presence or severity of disease. Using a Liver biopsy it is difficult to diagnose this condition because of the patchy nature of the disease. Investigators intend to identify hepatic and pancreatic fibrosis in Cystic Fibrosis patients using Elastography and correlate this with their biochemical markers as well as histological findings of patients who have undergone liver biopsy for diagnosis of CFALD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Liver disease is increasingly common in cystic fibrosis (CF). As new therapeutic options emerge, life expectancy increases and common hepatobiliary manifestations impact on quality of life and survival of CF patients. Hepatobiliary abnormalities in CF vary in nature and range from defects attributable to the underlying CFTR gene defect to those related to systemic disease and malnutrition. Today complications of liver disease represent the third most frequent cause of disease-related death in patients with CF.

Cystic fibrosis-associated liver disease (CFALD) belongs to the group of common symptoms of this disease; however, due to the lack of specific and sensitive CFALD diagnostic markers, the epidemiological data may be incomplete. According to various sources, the prevalence rate of CFALD, diagnosed on the basis of clinical, biochemical and imaging (ultrasonography) tests, is 2-37% in children and young adults.

Cirrhosis is a final, irreversible stage of liver damage that leads to the failure of the organ. While liver biopsy is considered the gold standard to assess for Hepatic Fibrosis; it is invasive and potentially life threatening. The prognosis and management of chronic liver disease depends on the extent and progression of liver fibrosis, which constitutes the most important predictor of disease outcome.

The gold standard for diagnosis and staging of liver fibrosis has been liver biopsy. In addition to being an invasive procedure with potential complications of bleeding and severe pain, sampling error is an intrinsic problem due to the small sample size in a heterogeneous process.7,8 Inter-observer variability also limits diagnostic consistency.9-11 The development of several blood markers such as platelets, hyaluronic acid, type IV collagen, aminotransferase/platelet ratio index (APRI) and algorithm based serum models (Fibro Index, FIB-4, and Fibro Test) have been used but are affected by factors unrelated to the liver.

In the last decade, methods to noninvasively quantify liver fibrosis have been developed. The first available method was transient elastography (TE).It is a single-element ultrasound transducer operating at 5 MHz built on the axis of a piston like vibrator. By pushing a button, low-frequency (50 Hz) transient vibrations are transmitted, and the generated elastic shear waves propagate through underlying tissues. Pulse-echo ultrasound acquisitions are used to follow the propagation of the shear wave and to measure its velocity .

Several studies have demonstrated a high accuracy of TE in identifying significant fibrosis (F\> 2) and cirrhosis (F= 4) in patients. It is a novel diagnostic tool that offers a rapid, non-invasive method for monitoring HF. The device measures liver stiffness by transmitting a vibration to determine the velocity of an elastic shear wave propagated through liver tissue.

Studies have documented utility of transient elastography in cystic fibrosis patients to assess hepatic fibrosis and secondary complications.

Newer modalities like Shear wave elastography techniques have been implemented in conventional real-time ultrasound systems, and several studies have shown their accuracy in the assessment of liver fibrosis. Shear wave elastography relies on the generation of shear waves determined by the displacement of tissues induced by the force of a focused ultrasound beam or by external pressure. The shear waves are lateral waves, with a motion perpendicular to the direction of the force that has generated them. They travel slowly (between 1 and 10 m/s) and are rapidly attenuated by tissue. The propagation velocity of the shear waves correlates with the elasticity of tissue .

Compared with TE, these techniques have the advantage of B-mode image guidance; thus, they can allow the user to choose the best acoustic window for correctly performing an examination in real time.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis Cystic Fibrosis Liver Disease Pancreatic Insufficiency Due to Cystic Fibrosis of Pancreas

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Patients (\<18 years) will be recruited from from the Children's Hospital Winnipeg CF clinic. Charts will be reviewed for demographic and clinical data including blood work. Each patient will undergo shear wave elastography by a trained operator.
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SIngle Arm

All patients undergo Elastography. This is a single arm study

Group Type OTHER

Elastography

Intervention Type DIAGNOSTIC_TEST

an ultrasound exam after selecting the best acoustic window, a region of interest (ROI) is placed in an area of the liver perpendicular to the liver capsule, taking care not to include large vasculature or biliary structures.

Similarly an acoustic window will be selected for the pancreas as well

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Elastography

an ultrasound exam after selecting the best acoustic window, a region of interest (ROI) is placed in an area of the liver perpendicular to the liver capsule, taking care not to include large vasculature or biliary structures.

Similarly an acoustic window will be selected for the pancreas as well

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \<18 years
* Confirmed diagnosis of cystic fibrosis attending Pediatric cystic fibrosis (CF) Clinic at Children's Hospital, Winnipeg.

Exclusion Criteria

* Children with age \>18 years
Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Manitoba

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Quais Mujawar

Pediatric Gastroenterologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Quais Mujawar

Role: PRINCIPAL_INVESTIGATOR

University of Manitoba

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Winnipeg Children's Hospital

Winnipeg, Manitoba, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Quais Mujawar

Role: CONTACT

Phone: 204-787-4950

Email: [email protected]

Vini Deora

Role: CONTACT

Phone: 204-787-4956

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Quais Mujawar

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B2017:077

Identifier Type: -

Identifier Source: org_study_id